Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Daniel Vitt
|
| gptkbp:clinicalTrialPhase |
multiple sclerosis
ulcerative colitis |
| gptkbp:developedBy |
IMU-838
IMU-856 IMU-935 |
| gptkbp:focusesOn |
immunology
autoimmune diseases |
| gptkbp:foundedIn |
Planegg-Martinsried, Germany
|
| gptkbp:foundedYear |
2016
|
| gptkbp:headquartersLocation |
gptkb:New_York,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunic
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
~50 (as of 2023)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
IMUX
|
| gptkbp:subsidiary |
Immunic AG
|
| gptkbp:website |
https://www.imux.com/
|
| gptkbp:bfsParent |
gptkb:MVentures
|
| gptkbp:bfsLayer |
8
|